PE20220381A1 - Formulacion de tableta vaginal - Google Patents
Formulacion de tableta vaginalInfo
- Publication number
- PE20220381A1 PE20220381A1 PE2021001545A PE2021001545A PE20220381A1 PE 20220381 A1 PE20220381 A1 PE 20220381A1 PE 2021001545 A PE2021001545 A PE 2021001545A PE 2021001545 A PE2021001545 A PE 2021001545A PE 20220381 A1 PE20220381 A1 PE 20220381A1
- Authority
- PE
- Peru
- Prior art keywords
- tablet formulation
- vaginal tablet
- vaginal
- gdl
- hypromellose
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000003 vaginal tablet Substances 0.000 title 1
- 229940044977 vaginal tablet Drugs 0.000 title 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 abstract 2
- 235000012209 glucono delta-lactone Nutrition 0.000 abstract 2
- 239000000182 glucono-delta-lactone Substances 0.000 abstract 2
- 229960003681 gluconolactone Drugs 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica solida que comprende de 5 a 30% p/p de glucono delta-lactona (GDL) y de 10 a 40% p/p de e hipromelosa (HPMC), la cual es adecuada para administracion vaginal y para el tratamiento de infecciones microbianas vaginales
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19167495 | 2019-04-05 | ||
| PCT/EP2020/059582 WO2020201515A1 (en) | 2019-04-05 | 2020-04-03 | Vaginal tablet formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220381A1 true PE20220381A1 (es) | 2022-03-18 |
Family
ID=66101895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001545A PE20220381A1 (es) | 2019-04-05 | 2020-04-03 | Formulacion de tableta vaginal |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12496288B2 (es) |
| EP (1) | EP3976000B1 (es) |
| JP (1) | JP7610847B2 (es) |
| KR (1) | KR102900830B1 (es) |
| CN (1) | CN113660928B (es) |
| AR (1) | AR118580A1 (es) |
| AU (1) | AU2020252268B2 (es) |
| BR (1) | BR112021019999A2 (es) |
| CA (1) | CA3134086A1 (es) |
| CL (1) | CL2021002430A1 (es) |
| CO (1) | CO2021014253A2 (es) |
| EA (1) | EA202192716A1 (es) |
| ES (1) | ES2961736T3 (es) |
| HU (1) | HUE062772T2 (es) |
| IL (1) | IL286942B2 (es) |
| MA (1) | MA56011A (es) |
| MX (1) | MX2021012146A (es) |
| MY (1) | MY208388A (es) |
| PE (1) | PE20220381A1 (es) |
| PH (1) | PH12021552462A1 (es) |
| PL (1) | PL3976000T3 (es) |
| SG (1) | SG11202110236QA (es) |
| TW (1) | TWI846854B (es) |
| UA (1) | UA127823C2 (es) |
| WO (1) | WO2020201515A1 (es) |
| ZA (1) | ZA202106877B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7424636B2 (ja) | 2017-10-06 | 2024-01-30 | ジェディア バイオテック エービー | 微生物感染症の治療および／または予防用グルコン酸誘導体 |
| WO2024261110A1 (en) * | 2023-06-22 | 2024-12-26 | Gedea Biotech Ab | Compositions for promoting growth of lactobacillus crispatus |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA90341B (en) * | 1989-01-23 | 1990-10-31 | Merrell Dow Pharma | Liquid pharmaceutical composition for piperidinoalkanol derivatives |
| FR2710265B1 (fr) * | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| ATE207755T1 (de) * | 1998-04-30 | 2001-11-15 | Vesely Renata Maria Cavaliere | Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen |
| US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| US20030017207A1 (en) * | 2001-05-01 | 2003-01-23 | Lin Shun Y. | Compositions and methods for treating vulvovaginitis and vaginosis |
| DE60219965T2 (de) * | 2002-04-23 | 2008-01-17 | Lupin Ltd., Mumbai | Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine |
| AU2003280065A1 (en) * | 2002-11-15 | 2004-06-15 | Eads Astrium Limited | Bupropion hydrochloride solid dosage forms |
| EP1872775A1 (en) | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
| ITBO20110461A1 (it) * | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| JP6967785B2 (ja) * | 2016-04-06 | 2021-11-17 | ジェディア バイオテック エービー | 膣真菌感染症の治療のためのグルコノデルタ−ラクトン |
| JP7424636B2 (ja) | 2017-10-06 | 2024-01-30 | ジェディア バイオテック エービー | 微生物感染症の治療および／または予防用グルコン酸誘導体 |
-
2020
- 2020-04-03 JP JP2021560220A patent/JP7610847B2/ja active Active
- 2020-04-03 EP EP20715885.8A patent/EP3976000B1/en active Active
- 2020-04-03 PE PE2021001545A patent/PE20220381A1/es unknown
- 2020-04-03 CN CN202080027260.1A patent/CN113660928B/zh active Active
- 2020-04-03 KR KR1020217033774A patent/KR102900830B1/ko active Active
- 2020-04-03 SG SG11202110236QA patent/SG11202110236QA/en unknown
- 2020-04-03 US US17/601,521 patent/US12496288B2/en active Active
- 2020-04-03 HU HUE20715885A patent/HUE062772T2/hu unknown
- 2020-04-03 EA EA202192716A patent/EA202192716A1/ru unknown
- 2020-04-03 BR BR112021019999A patent/BR112021019999A2/pt unknown
- 2020-04-03 IL IL286942A patent/IL286942B2/en unknown
- 2020-04-03 ES ES20715885T patent/ES2961736T3/es active Active
- 2020-04-03 UA UAA202106160A patent/UA127823C2/uk unknown
- 2020-04-03 MY MYPI2021005940A patent/MY208388A/en unknown
- 2020-04-03 AR ARP200100936A patent/AR118580A1/es unknown
- 2020-04-03 CA CA3134086A patent/CA3134086A1/en active Pending
- 2020-04-03 WO PCT/EP2020/059582 patent/WO2020201515A1/en not_active Ceased
- 2020-04-03 PL PL20715885.8T patent/PL3976000T3/pl unknown
- 2020-04-03 PH PH1/2021/552462A patent/PH12021552462A1/en unknown
- 2020-04-03 MX MX2021012146A patent/MX2021012146A/es unknown
- 2020-04-03 AU AU2020252268A patent/AU2020252268B2/en active Active
- 2020-04-03 MA MA056011A patent/MA56011A/fr unknown
- 2020-04-06 TW TW109111529A patent/TWI846854B/zh active
-
2021
- 2021-09-17 ZA ZA2021/06877A patent/ZA202106877B/en unknown
- 2021-09-20 CL CL2021002430A patent/CL2021002430A1/es unknown
- 2021-10-25 CO CONC2021/0014253A patent/CO2021014253A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| CY1109910T1 (el) | Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων | |
| WO2018165404A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX2023009833A (es) | Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas. | |
| MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
| PE20220381A1 (es) | Formulacion de tableta vaginal | |
| AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
| BR112022014772A2 (pt) | Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| CL2018002705A1 (es) | Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales | |
| MX2020000009A (es) | Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos. | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| MY191983A (en) | Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same | |
| ECSP22092205A (es) | Composición farmacéutica acuosa de levilimab y su uso | |
| BR112021026471A2 (pt) | Formulações de dose sólida para a liberação sem agulha | |
| CY1113544T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος | |
| ES2280150T1 (es) | Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma. | |
| NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
| BR112021024054A2 (pt) | Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos. | |
| CL2023000110A1 (es) | Composición farmacéutica acuosa que comprende un antagonista del receptor p2y12 | |
| MX2025014461A (es) | Dispersion solida de inhibidor del eed, formulacion oral que la comprende y metodo de preparacion para esta | |
| TR2021013229A2 (tr) | Geli̇şti̇ri̇lmi̇ş çözünme hizina sahi̇p kanagli̇flozi̇n hemi̇hi̇drat i̇çeren fi̇lm kapli tablet formülasyonlari | |
| AR123553A1 (es) | Formas farmacéuticas sólidas con perfiles de disgregación mejorados | |
| WO2022146355A3 (en) | Pharmaceutical capsule compositions of alogliptine |